Lung Cancer

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.